Larimar Therapeutics, Inc. (LRMR) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Bala Cynwyd, PA, アメリカ. 現CEOは Carole S. Ben-Maimon.
LRMR を有する IPO日 2014-06-19, 65 名の正社員, に上場 NASDAQ Global Market, 時価総額 $416.77M.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
